Potyvirus

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Retrieved on: 
星期三, 五月 29, 2024
Patient, Infection, Mesothelioma, Neuroblastoma, Measles, Human, Toxicity, Science, HPV, RNA, Clinical trial, Fruit, Vaccine, Research, Potyvirus, Pasteur Institute, Virus, GMP

Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.

Key Points: 
  • Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.
  • Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of new vaccines based on MeasovirR technology, based on the measles vaccine virus.
  • The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate   the first clinical trial.
  • The joint Institut Pasteur - Oncovita laboratory will also be carrying out research into viral defective interfering RNAs (DI-RNAs) produced by modified recombinant measles viruses.

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

Retrieved on: 
星期二, 五月 28, 2024
Merck & Co., Interleukin, Patient, Survival, Lymphocyte, Pembrolizumab, Ovarian cancer, Immune system, Neoplasm, PFS, TILT, Safety, RECIST, Assistant, Cancer, Potyvirus, ASCO, Merck, Health Affairs, Abstract, OS, Society, Pharmaceutical industry

HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
  • Abstract (5562) demonstrates promising safety and efficacy data of TILT-123 in ovarian cancer patients, whilst abstract (2658) demonstrates the potential for TILT-123 as an intravenous therapy.
  • 14 patients (out of 15 enrolled) were evaluable for treatment response, with disease control achieved in 64.3%.
  • This means TILT-123 reached tumors, despite not being directly injected into them, and successfully triggered an immune system toward the cancer.

Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight to 2030 - Regulatory Approvals and Pharmaceutical Investments Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 五月 27, 2024
FDA, Pharmaceutical, Health, Oncology, Pembrolizumab, Patient, Nanoparticle, Oncolytic virus, Immunotherapy, Astellas Pharma, NRG, Laboratory, Glioma, Investment, Candel, H101, Immune system, Bristol Myers Squibb, Therapy, Government, Head, Snow, Breast cancer, Optimism, Genelux Corporation, Growth, PD-1, Cancer, Potyvirus, Irinotecan, Pancreatic cancer, EMA, Melanoma, Research, Fast Track, Attention, Merck, Oncos, Gastrointestinal cancer, OH2, Roche, Indication, Virus, PD-L1, Antibody, Quality of life, Vaccine

The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.
  • As the global medical community continues to advance targeted cancer therapies, oncolytic virus immunotherapy has emerged as a seminal player in this dynamic field.
  • Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion by 2030
    Oncolytic Viruses Immunotherapies Clinical Trials by Company, Indication & Phase
    Comprehensive Insight on Oncolytic Virus Immunotherapies in Clinical Trials: > 180 Therapies
    Cancer endures to be a relentless adversary, challenging both patients and the medical community across the world.
  • Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy.

Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024: Cusatuzumab Emerges as Leading Phase II Candidate for Leukemia Treatment, Paving the Way for CD70 Therapy Evolution - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 7, 2024
Health, Oncology, Factorization of polynomials, Zhejiang University, FTD, Cancer, Investment, Nanchang University, Hospital, Survival, Partnership, Research, Leukemia, PI3K, Indication, Patient, Neoplasm, Potyvirus, CD70, MAP, Antibody, Medicine, Gene, CB, Pharmaceutical industry

The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, numerous pharma and biotech companies planned to develop CD70 therapy and initiated clinical trials.
  • Over the preceding decennium, the sphere of global CD70 therapy market has witnessed the development of several novel, innovative as well as advanced contenders targeting CD70.
  • The combinational study for CD70 therapy represents a novel as well as compelling frontier in the commercial CD70 therapy landscape.

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Retrieved on: 
星期三, 四月 10, 2024
Cancer, Interleukin, Pembrolizumab, Merck & Co., Pancreatic serous cystadenoma, Tumor microenvironment, Immunoglobulin E, Patient, TILT, B cell, Potyvirus, Immunomodulation, AACR, Neoplasm, Merck, Ovarian cancer, Injection, Platinum, Pharmaceutical industry

HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • Analysis of biological samples revealed insights into mechanism of action, including an immunological profile potentially predictive of clinical response.
  • The results presented at AACR 2024, along with data from other ongoing trials, underscore the promise of TILT-123 as a novel cancer therapy.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

Retrieved on: 
星期三, 三月 27, 2024
MSD, Research, Conference call, Conference, Head, AstraZeneca, E7, Patient, Merck & Co., Tumor microenvironment, Merck, News, R&I, Cancer, Virus, MD, E6, Lung cancer, AACR, NEC, European Journal, HPV16, Euronext Paris, De novo, Immune system, ASCO, Safety, Poster, Potyvirus, Pharmaceutical industry

Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.

Key Points: 
  • Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
  • “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
  • As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
  • In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Retrieved on: 
星期二, 四月 9, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, B cell, Immunity, Cell, Patient, City, Tumor microenvironment, Cancer, AACR, Chemokine, Clinical trial, Immune system, Virus, Potyvirus, Poster, Vaccine

The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.

Key Points: 
  • The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
  • “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
  • In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
  • This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.

Mike Grey appointed Executive Chair of Theolytics' Board of Directors

Retrieved on: 
星期四, 三月 21, 2024
Ovarian cancer, Eli Lilly, Chair, Biotechnology, Patient, Drug development, Potyvirus, Corporate development, Pharmaceutical industry

OXFORD, England, March 21, 2024 /PRNewswire/ -- Theolytics, a biotechnology company developing category changing cancer therapies in the form of oncolytic viruses, today announced the appointment of Michael (Mike) Grey succeeding Dr. Ken Powell, who is retiring from the Board having served as Chair since 2019.

Key Points: 
  • THEO-260 is an oncolytic adenovirus that has demonstrated compelling efficacy in preclinical studies, selected to be effective in stromal-rich solid tumors, combined with systemic, intravenous delivery potential.
  • "Mike brings a wealth of experience to Theolytics" said Charlotte Casebourne Stock, Chief Executive Officer of Theolytics.
  • "I am delighted to be joining Theolytics at this important time, as our lead programme is scheduled to start clinical studies mid-2024" said Mike Grey, Executive Chair of the Board of Directors at Theolytics.
  • Mike has founded several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Inc., Sorriso Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc., Spruce Biosciences, Inc. and Plexium Inc.

Mike Grey appointed Executive Chair of Theolytics' Board of Directors

Retrieved on: 
星期四, 三月 21, 2024
Ovarian cancer, Eli Lilly, Chair, Biotechnology, Patient, Drug development, Potyvirus, Corporate development, Pharmaceutical industry

OXFORD, England, March 21, 2024 /PRNewswire/ -- Theolytics, a biotechnology company developing category changing cancer therapies in the form of oncolytic viruses, today announced the appointment of Michael (Mike) Grey succeeding Dr. Ken Powell, who is retiring from the Board having served as Chair since 2019.

Key Points: 
  • THEO-260 is an oncolytic adenovirus that has demonstrated compelling efficacy in preclinical studies, selected to be effective in stromal-rich solid tumors, combined with systemic, intravenous delivery potential.
  • "Mike brings a wealth of experience to Theolytics" said Charlotte Casebourne Stock, Chief Executive Officer of Theolytics.
  • "I am delighted to be joining Theolytics at this important time, as our lead programme is scheduled to start clinical studies mid-2024" said Mike Grey, Executive Chair of the Board of Directors at Theolytics.
  • Mike has founded several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Inc., Sorriso Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc., Spruce Biosciences, Inc. and Plexium Inc.

FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer

Retrieved on: 
星期一, 三月 11, 2024
CFO, Head, Potyvirus, Life, Growth, Novo Nordisk, Alston & Bird, Vaccine, CDMO, History, Financial management, Small Business Saturday, Partner, Fujifilm Diosynth Biotechnologies, Management

In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.

Key Points: 
  • In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.
  • We look forward to Richard’s contributions as we execute on our growth strategy," said Lars Petersen, president and chief executive officer of FUJIFILM Diosynth Biotechnologies.
  • Prior to joining FUJIFILM Diosynth Biotechnologies, he held leadership roles at Novo Nordisk and Alston & Bird LLP.
  • To find more information on all members of the FUJIFILM Diosynth Biotechnologies Executive Leadership team please visit: www.fujifilmdiosynth.com/leadership